An open-label study to investigate the excretion and metabolic disposition of a single, oral dose of [14C]-SB-751689 [ronacaleret] (a calcium-sen.sing receptor antagonist) in healthy male subjects and healthy postmenopausal female subjects
Latest Information Update: 27 Jun 2023
At a glance
- Drugs Ronacaleret (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2008 Actual end date for this trial is now Jul 2007 as reported by ClinicalTrials.gov
- 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 10 Aug 2007 New trial record.